The FDA is now cautioning about the use of albumin or plasma protein fraction (PPF) in seriously ill patients

The FDA is now cautioning about the use of albumin or plasma protein fraction (PPF) in seriously ill patients.

A new meta-analysis in the British Medical Journal suggests a 6% HIGHER mortality when albumin is given to seriously ill patients with hypovolemia...burns...or hypoproteinemia. This would mean one excess death per 17 treated patients.

Researchers suspect this may be partly due to the leakage of albumin and water from capillaries...leading to pulmonary edema, poor tissue oxygenation, and multiorgan failure.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote